Korean J Hematol.  2012 Sep;47(3):237-238. 10.5045/kjh.2012.47.3.237.

Prognostic relevance of pericardial effusion in patients with malignant diseases

• Jeong TD
• Jang S
• Park CJ
• Chi HS

• KMID: 2251961
• DOI: http://doi.org/10.5045/kjh.2012.47.3.237

Abstract

No abstract available.

MeSH Terms

Humans
Pericardial Effusion

Figure

• 

  Fig. 1 Overall survival according to pericardial involvement in the malignant disease. The pericardial involvement group had a significantly poorer survival rate than the non-pericardial involvement group (Pa, pericardial involvement group vs. non-pericardial involvement group).

Reference

1. Gornik HL, Gerhard-Herman M, Beckman JA. Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol. 2005. 23:5211–5216.

2. Halfdanarson TR, Hogan WJ, Moynihan TJ. Oncologic emergencies: diagnosis and treatment. Mayo Clin Proc. 2006. 81:835–848.

3. Dequanter D, Lothaire P, Berghmans T, Sculier JP. Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival. Ann Surg Oncol. 2008. 15:3268–3271.

4. Kim SH, Kwak MH, Park S, et al. Clinical characteristics of malignant pericardial effusion associated with recurrence and survival. Cancer Res Treat. 2010. 42:210–216.

5. Maisch B, Ristic A, Pankuweit S. Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis. 2010. 53:157–163.